TABLE 2

Compilation of metrics for FDA-approved small-molecule drugs 2006–2015

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	Totals
Active ingredients	16	15	21	21	12	24	28	22	31	31	221
Other route(s)	2	3	4	4	1	3	4	3	4	2	30
Intravenous	1	3	7	3	4	2	3	2	6	4	35
Imaging agents	0	0	4	0	0	2	2	2	1	0	11
Prodrugs	0	2	2	1	1	0	0	0	0	0	6
No ADME study	0	0	0	1	0	0	1	0	4	0	6
Insufficient data	0	0	1	0	1	0	0	0	0	1	3
Compounds evaluated	1	2	0	1	2	0	0	0	1	3	10
Oral	13	9	10^{^a}	14	7	19	21	17	21^{^a}	25^{^a}	156
Prodrugs	0	0	1	1	2	3	0	2	1	6	16
No ADME study	1	1	1	2	0	2	3	0	3	3	16
Insufficient data	3	0	0	0	0	1	1	1	0	2	8
Compounds evaluated	9	7	8	11	5	13	17	14	17	14	115

↵^a Lacosamide, tedizolid phosphate, and isavuconazonium sulfate are administered either orally or intravenously. For simplicity, these drugs were only counted in the oral category.